Form 4: Orchestra BioMed Holdings Director Receives Stock Awards

Director David Pacitti receives stock options and restricted stock units from Orchestra BioMed Holdings.

Summary

• David Pacitti, a director at Orchestra BioMed Holdings, received 10,000 restricted stock units (RSUs) and options to purchase 34,633 shares of common stock on March 26, 2024.
• The RSUs vest in installments, with 2,000 vesting on June 20, 2024, and the remaining 8,000 vesting in three equal annual installments starting on the first anniversary of the vesting date.
• Similarly, 7,302 of the stock options vest on June 20, 2024, with the remaining 27,331 vesting in three equal annual installments starting on the first anniversary of the vesting date.
• The exercise price for the stock options is $5.
• Following the transaction, Pacitti directly owns 12,170 shares of common stock and 34,633 stock options.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard compensation practices and aligns director interests with shareholders.

Positives

• The grant of RSUs and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

Stock awards to directors are a common practice in publicly traded companies to incentivize performance and align interests with shareholders.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice across the biotechnology industry.
• The vesting schedules are typical, designed to retain key personnel and align their interests with long-term shareholder value.
• Comparable companies such as Medtronic or Boston Scientific also utilize stock options and RSU's as part of their compensation packages for directors.

Stakeholder Impact

• The stock awards incentivize the director to work towards increasing shareholder value.
• The vesting schedule encourages long-term commitment to the company.

Key Dates